Postgenomic research on leishmaniasis: a critical self-appraisal

Trends in Parasitology

Volumn 24, Issue 9, 2008, Pages 401-405

  Kaye, Paul M ^a   Blackwell, Jenefer M ^b  

^a UNIVERSITY OF HULL   (United Kingdom)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; AWARENESS; CLINICAL RESEARCH; DISEASE MODEL; GENOMICS; HUMAN; IMMUNE RESPONSE; LEISHMANIA; LEISHMANIASIS; MALARIA; MORTALITY; MYCOPLASMA; NONHUMAN; PARASITE TRANSMISSION; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PUBLIC HEALTH PROBLEM;

ANIMALS; DISEASE MODELS, ANIMAL; GENOME, PROTOZOAN; LEISHMANIA; LEISHMANIASIS; MICE; RESEARCH;

EID: 49449108714     PISSN: 14714922     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pt.2008.06.004     Document Type: Article

References (34)

1. Alvar J., et al. Leishmaniasis and poverty. Trends Parasitol. 22 (2006) 552-557
2. Chappuis F., et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?. Nat. Rev. Microbiol. 5 (2007) 873-882
3. Cruz I., et al. Leishmania/HIV co-infections in the second decade. Indian J. Med. Res. 123 (2006) 357-388
4. Peacock C.S., et al. Comparative genomic analysis of three Leishmania species that cause diverse human disease. Nat. Genet. 39 (2007) 839-847
5. Berriman M., et al. The genome of the African trypanosome Trypanosoma brucei. Science 309 (2005) 416-422
6. El-Sayed N.M., et al. The genome sequence of Trypanosoma cruzi, etiologic agent of Chagas disease. Science 309 (2005) 409-415
7. El-Sayed N.M., et al. Comparative genomics of trypanosomatid parasitic protozoa. Science 309 (2005) 404-409
8. Ivens A.C., et al. The genome of the kinetoplastid parasite. Leishmania major. Science 309 (2005) 436-442
9. Beattie L., et al. Transgenic Leishmania and the immune response to infection. Parasite Immunol. 30 (2008) 255-266
10. Smith D.F., et al. Comparative genomics: from genotype to disease phenotype in the leishmaniases. Int. J. Parasitol. 37 (2007) 1173-1186
11. Yao C., et al. Leishmania chagasi: a tetracycline-inducible cell line driven by T7 RNA polymerase. Exp. Parasitol. 116 (2007) 205-213
12. Croft S.L., et al. Current scenario of drug development for leishmaniasis. Indian J. Med. Res. 123 (2006) 399-410
13. Jeronimo S.M., et al. Genes at human chromosome 5q31.1 regulate delayed-type hypersensitivity responses associated with Leishmania chagasi infection. Genes Immun. 8 (2007) 539-551
14. Mohamed H.S., et al. Genetic susceptibility to visceral leishmaniasis in The Sudan: linkage and association with IL4 and IFNGR1. Genes Immun. 4 (2003) 351-355
15. Mohamed H.S., et al. SLC11A1 (formerly NRAMP1) and susceptibility to visceral leishmaniasis in The Sudan. Eur. J. Hum. Genet. 12 (2004) 66-74
16. Sacks D., and Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat. Rev. Immunol. 2 (2002) 845-858
17. Zhang W.W., and Matlashewski G. Characterization of the A2-A2rel gene cluster in Leishmania donovani: involvement of A2 in visceralization during infection. Mol. Microbiol. 39 (2001) 935-948
18. Garg R., and Dube A. Animal models for vaccine studies for visceral leishmaniasis. Indian J. Med. Res. 123 (2006) 439-454
19. Belkaid Y., et al. CD8+ T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major. J. Immunol. 168 (2002) 3992-4000
20. Belkaid Y., et al. Development of a natural model of cutaneous leishmaniasis: powerful effects of vector saliva and saliva preexposure on the long-term outcome of Leishmania major infection in the mouse ear dermis. J. Exp. Med. 188 (1998) 1941-1953
21. Rogers M.E., et al. Transmission of cutaneous leishmaniasis by sand flies is enhanced by regurgitation of fPPG. Nature 430 (2004) 463-467
22. Kaye P.M., et al. The immunopathology of experimental visceral leishmaniasis. Immunol. Rev. 201 (2004) 239-253
23. Sacks D., and Kamhawi S. Molecular aspects of parasite-vector and vector-host interactions in leishmaniasis. Annu. Rev. Microbiol. 55 (2001) 453-483
24. Valenzuela J.G., et al. Toward a defined anti-Leishmania vaccine targeting vector antigens: characterization of a protective salivary protein. J. Exp. Med. 194 (2001) 331-342
25. Engwerda C.R., and Kaye P.M. Organ-specific immune responses associated with infectious disease. Immunol. Today 21 (2000) 73-78
26. Nylen S., et al. Surrogate markers of immunity to Leishmania major in leishmanin skin test negative individuals from an endemic area re-visited. Vaccine 24 (2006) 6944-6954
27. Darrah P.A., et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat. Med. 13 (2007) 843-850
28. Kenney R.T., et al. Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis. J. Immunol. 163 (1999) 4481-4488
29. Ismail A., et al. Pathology of post-kala-azar dermal leishmaniasis: a light microscopical, immunohistochemical, and ultrastructural study of skin lesions and draining lymph nodes. J. Cutan. Pathol. 33 (2006) 778-787
30. el Hassan A.M., et al. The pathology of cutaneous leishmaniasis in The Sudan: a comparison with that in other geographical areas. Ann. Trop. Med. Parasitol. 90 (1996) 485-490
31. Adhikari S.R., and Maskay N.M. The economic burden of kala-azar in households of the Danusha and Mahottari districts of Nepal. Acta Trop. 88 (2003) 1-2
32. Boelaert M., et al. How better drugs could change kala-azar control. Lessons from a cost-effectiveness analysis. Trop. Med. Int. Health 7 (2002) 955-959
33. Vanlerberghe V., et al. Drug policy for visceral leishmaniasis: a cost-effectiveness analysis. Trop. Med. Int. Health 12 (2007) 274-283
34. Blackwell J.M., et al. Molecular biology of Leishmania. Parasitol. Today 2 (1986) 45-53